G
Giuseppe Luigi Banna
Researcher at Queen Alexandra Hospital
Publications - 207
Citations - 4640
Giuseppe Luigi Banna is an academic researcher from Queen Alexandra Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 27, co-authored 156 publications receiving 2905 citations. Previous affiliations of Giuseppe Luigi Banna include Yahoo! & University of Naples Federico II.
Papers
More filters
Journal ArticleDOI
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Marina Chiara Garassino,Jennifer G. Whisenant,Li-Ching Huang,Annalisa Trama,Valter Torri,Francesco Agustoni,Javier Baena,Giuseppe Luigi Banna,Rossana Berardi,Anna Cecilia Bettini,Emilio Bria,Matteo Brighenti,Jacques Cadranel,Alessandro De Toma,Claudio Chini,Alessio Cortellini,Enriqueta Felip,Giovanna Finocchiaro,Pilar Garrido,Carlo Genova,Raffaele Giusti,Vanesa Gregorc,Francesco Grossi,Federica Grosso,Salvatore Intagliata,Nicla La Verde,Stephen V. Liu,Julien Mazieres,Edoardo Mercadante,Olivier Michielin,Gabriele Minuti,Denis Moro-Sibilot,Giulia Pasello,Antonio Passaro,Vieri Scotti,Piergiorgio Solli,Elisa Stroppa,Marcello Tiseo,Giuseppe Viscardi,Luca Voltolini,Yi-Long Wu,Silvia Zai,Vera Pancaldi,Anne Marie C. Dingemans,Jan P. van Meerbeeck,Fabrice Barlesi,Heather A. Wakelee,Solange Peters,Leora Horn +48 more
TL;DR: With an ongoing global pandemic of COVID-19, the data suggest high mortality and low admission to intensive care in patients with thoracic cancer and whether mortality could be reduced with treatment in intensive care remains to be determined.
Journal ArticleDOI
Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme
Roberto Pallini,Lucia Ricci-Vitiani,Giuseppe Luigi Banna,Michele Signore,Dario Giuseppe Lombardi,Matilde Todaro,Giorgio Stassi,Maurizio Martini,Giulio Maira,Luigi Maria Larocca,Ruggero De Maria +10 more
TL;DR: The analysis of CSCs may predict the survival of glioblastoma patients and in vitro CSC generation and presence of CD133+/Ki67+ cells are two considerable prognostic factors of disease progression and poor clinical outcome.
Journal ArticleDOI
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Silvia Vivarelli,Rossella Salemi,Saverio Candido,Luca Falzone,Maria Santagati,Stefania Stefani,Francesco Torino,Giuseppe Luigi Banna,Giuseppe Tonini,Massimo Libra +9 more
TL;DR: Novel strategies integrating probiotics, such as LGG, with conventional anti-cancer therapies are strongly encouraged, because of the tight association between gut microbiota and tumorigenesis, as well as Gut microbiota and anti- cancer therapy.
Journal ArticleDOI
Anticancer oral therapy: Emerging related issues
Giuseppe Luigi Banna,Elena Collovà,Vittorio Gebbia,Helga Lipari,Pietro Giuffrida,Sebastiano Cavallaro,Rosaria Condorelli,Calogero Buscarino,Paolo Tralongo,F. Ferraù +9 more
TL;DR: Current evidences show similar quality of life profile between oral and intravenous treatments, although anticancer oral therapy seems to be more convenient in terms of administration and reduced time lost for work or other activities.
Journal ArticleDOI
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Cora N. Sternberg,Yohann Loriot,Nicholas D. James,Ernest Choy,Daniel Castellano,Fernando Lopez-Rios,Giuseppe Luigi Banna,Ugo De Giorgi,Cristina Masini,Aristotelis Bamias,Xavier Garcia del Muro,Ignacio Duran,Thomas Powles,Marija Gamulin,Friedemann Zengerling,Lajos Géczi,Craig Gedye,Sabine de Ducla,Simon Fear,Axel S. Merseburger +19 more
TL;DR: Efficacy overall and in the IMvigor211-like subgroup is consistent with previous pivotal anti-PD-L1/PD-1 urothelial carcinoma trials, and results support the use of atezolizumab in urinary tract carcinoma, including patients with limited treatment options.